The 'twincretin' tirzepatide (Mounjaro) met its primary endpoints compared with placebo in the SURMOUNT-2 trial, designed to test weight loss efficacy, in top-line results reported by Lilly.

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

Eli Lilly’s trending weight loss candidate tirzepatide has scored its second pivotal trial win—once again with impressive results.. Also known as Mounjaro when marketed as a Type 2 diabetes ...

Preliminary data from a large Phase 3 clinical trial is offering promising signs for a new anti-obesity drug. Called tirzepatide, the drug helped overweight and obese participants lose up to 22.5 ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

The twincretin tirzepatide produced jaw-dropping levels of weight loss in people with obesity and no diabetes compared with placebo in the SURMOUNT-1 pivotal trial with more than 2500 participants.

In this trial, both drugs helped improve these health markers, but tirzepatide’s added benefits could make it the top choice for many people with obesity. Still, not every patient will need the ...

Pharmaceutical company Eli Lilly last week disclosed the latest data from a phase III trial of its experimental type 2 diabetes and obesity drug, tirzepatide: People who took the drug lost up to ...

Mean change in AHI at week 52 among the PAP users (trial 2) was -29.3 events per hour with tirzepatide compared with -5.5 events with placebo (estimated treatment difference -23.8 events, 95% CI ...